Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
03 January 2017Website:
http://www.panbela.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Mon, 01 Jul 2024 19:56:55 GMTDividend
Analysts recommendations
Institutional Ownership
PBLA Latest News
MINNEAPOLIS, June 24, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the independent Data Safety Monitoring Board (DSMB) has completed its third pre-specified safety review of the ongoing Phase 3 ASPIRE clinical trial evaluating ivospemin in combination with gemcitabine and nab-Paclitaxel for the first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC). The DSMB recommended study continuation without modification, marking the third consecutive positive safety review. The safety database now includes 395 patients, compared to 214 patients on November 29, 2023.
Panbela Therapeutics, Inc. (OTC:PBLA) Q1 2024 Earnings Conference Call on May 15, 2024 at 4:30 PM ET with Company Representatives James Carbonara - IR, HaydenIR, Jennifer Simpson - President & CEO, and Susan Horvath - CFO. Conference Call Participants include Jonathan Aschoff from Roth Capital Partners. Operator greets attendees and introduces the call.
Panbela Therapeutics, Inc. (PBLA) Q4 2023 Earnings Call Transcript
MINNEAPOLIS, March 12, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on March 26, 2024, at 4:30 PM Eastern Time to discuss results for its fourth quarter and year ended December 31, 2023.
Panbela Therapeutics (NASDAQ: PBLA ) stock is falling on Monday after the clinical-stage biopharmaceutical company revealed the pricing of a public offering for its shares. Panbela Therapeutics is selling 4,375,000 shares of its common stock for $2.06 each.
Shares of Panbela Therapeutics Inc. PBLA, +55.45% dropped 21.7% in premarket trading, as they paused after a two-day “meme”-like rally of 243.5%. The two-day rally in the biopharmaceutical company's stock, which followed a record-low close of 45.7 cents on Friday, was fueled by positive news from the U.S. Food and Drug Administration regarding a treatment for child cancer.
Shares of Panbela Therapeutics Inc. skyrocketed again Tuesday, following positive news from the U.S. Food and Drug Administration regarding a treatment for child cancer.
Panbela Therapeutics, Inc. (NASDAQ:PBLA ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants James Carbonara - IR Jennifer Simpson - CEO Sue Horvath - CFO Conference Call Participants Jonathan Aschoff - ROTH MKM Operator Greetings, and welcome to the Panbela Therapeutics Third Quarter 2023 Earnings Call. [Operator Instructions] Please note this conference is being recorded.
MINNEAPOLIS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on November 9, 2023, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2023.
MINNEAPOLIS, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announced that management will be presenting virtually at the H.C. Wainwright 25th Annual Global Investment Conference.
What type of business is Panbela Therapeutics?
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
What sector is Panbela Therapeutics in?
Panbela Therapeutics is in the Healthcare sector
What industry is Panbela Therapeutics in?
Panbela Therapeutics is in the Biotechnology industry
What country is Panbela Therapeutics from?
Panbela Therapeutics is headquartered in United States
When did Panbela Therapeutics go public?
Panbela Therapeutics initial public offering (IPO) was on 03 January 2017
What is Panbela Therapeutics website?
https://www.panbela.com
Is Panbela Therapeutics in the S&P 500?
No, Panbela Therapeutics is not included in the S&P 500 index
Is Panbela Therapeutics in the NASDAQ 100?
No, Panbela Therapeutics is not included in the NASDAQ 100 index
Is Panbela Therapeutics in the Dow Jones?
No, Panbela Therapeutics is not included in the Dow Jones index
When does Panbela Therapeutics report earnings?
The next expected earnings date for Panbela Therapeutics is 09 August 2024